Encephalitis Symptoms Masked as Worsening Parkinson’s Disease, Case Report Shows

Parkinson’s disease can sometimes mask the symptoms of other neurological disorders, according to a case report. The report, titled “NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease,” documents the case of a 71-year-old woman who was eventually diagnosed with encephalitis, the symptoms of which were first thought to be caused by a

Targeting Enzyme Has Potential as Parkinson’s Therapy, Yumanity Announces

Blocking a key enzyme responsible for the production of a type of fat can become a potential therapeutic approach to treat Parkinson’s disease, Yumanity Therapeutics recently announced. The company revealed that inhibiting an enzyme called stearoyl-CoA desaturase can protect human neurons from alpha-synuclein-derived toxicity and improve their survival. Based on these promising results, the company plans to initiate

Nicotine May Protect the Brain from Toxic Trace Metals Linked to Parkinson’s, Cell Study Finds

Nicotine may protect the brain from manganese and iron metal trace elements thought to be involved in the onset of Parkinson’s disease, a study based on a disease cell model reported. The study, “Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson’s disease,” was published in Neurochemistry International. Parkinson’s is characterized by

Dietary Supplements May Help Control Metabolism, Brain Inflammation in Parkinson’s, Study Finds

Supplements of omega-3 fatty acids and vitamin E may help control genes involved in brain inflammation and body metabolism in patients with Parkinson’s disease, a study has found. The study, “The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: A randomized,

Parkinson’s Patients Show Reduced Workforce Participation Even Before Diagnosis, Study Finds

Parkinson’s patients show less ability to participate in work life even in the early stages before they are diagnosed with the disease, a study shows. In combination with biochemical and genetic biomarkers, this finding may help identify patients at risk of developing this progressive neurodegenerative disease before motor symptoms occur, the researchers suggest. The study,

New Art Initiative Aims to Improve Understanding and Discussion of Parkinson’s Off Periods

A new initiative by Acorda Therapeutics uses art to help people with Parkinson’s disease recognize and communicate about their off-period experiences. The initiative, called Framing OFF Through Art, builds on Acorda’s Live Well. Do Tell program, launched earlier this year. Framing OFF Through Art includes artwork inspired by the experiences of patients with Parkinson’s and their caregivers. The

Phase 1 Trial to Explore RDN-929’s Safety in Treating Brain Diseases by Protecting Synapses

Rodin Therapeutics has started a Phase 1 clinical trial to explore the safety of its synthetic compound, RDN-929, to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, by protecting synapses. The trial (NCT03668314), is designed to assess the safety, tolerability, pharmacokinetics — how the body affects a medicine — and pharmacodynamics — the interactions between the body and a

Caffeine Plus Coffee Compound Linked to Serotonin Help Protect Brain from Toxic Damage, Mouse Study Says

Two compounds found in coffee — caffeine and EHT, a fatty acid molecule derived from serotonin — work together to protect the brain from damage induced by alpha-synuclein, a study in mice reported. The study, “Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and DLB,” was published in PNAS. Parkinson’s disease